| __timestamp | Novartis AG | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 504755000 |
| Thursday, January 1, 2015 | 14247000000 | 838526000 |
| Friday, January 1, 2016 | 14192000000 | 1177697000 |
| Sunday, January 1, 2017 | 14997000000 | 1320433000 |
| Monday, January 1, 2018 | 16471000000 | 1556200000 |
| Tuesday, January 1, 2019 | 14369000000 | 1834800000 |
| Wednesday, January 1, 2020 | 14197000000 | 1346000000 |
| Friday, January 1, 2021 | 14886000000 | 1824900000 |
| Saturday, January 1, 2022 | 14253000000 | 2115900000 |
| Sunday, January 1, 2023 | 12489000000 | 2631300000 |
| Monday, January 1, 2024 | 12566000000 | 2954400000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Over the past decade, Novartis AG and Regeneron Pharmaceuticals, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Novartis, a Swiss multinational, has seen its SG&A expenses fluctuate, peaking in 2018 with a 10% increase from 2014, before declining by 24% in 2023. Meanwhile, Regeneron, an American biotechnology company, has experienced a consistent upward trajectory, with a staggering 421% increase in SG&A expenses from 2014 to 2023. This divergence highlights differing strategic priorities: Novartis appears to be optimizing its operational costs, while Regeneron is investing heavily in growth. As the pharmaceutical industry evolves, these trends offer valuable insights into how companies balance cost management with expansion strategies.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and GSK plc
Regeneron Pharmaceuticals, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. vs Jazz Pharmaceuticals plc: SG&A Expense Trends
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Veracyte, Inc.